US-FDA and EMA approved
Neratinib is an oral, irreversible inhibitor of Human Epidermal Growth Factor Receptors (HER 1, 2, 4).
It is used to treat adults with:
- Early stage HER2 positive breast cancer and have previously been treated with trastuzumab-based therapy.
- Metastatic HER2 positive breast cancer along with capecitabine, and who have received 2 or more anti-HER2 therapy medications.